X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
TACH101 is a novel, potent small molecule inhibitor of KDM4, a novel epigenetic target for cancer therapy. KDM4 is a family of histone lysine demethylases that, when overexpressed, drives key processes linked to cancer.
Lead Product(s): TACH101
Therapeutic Area: Oncology Product Name: TACH101
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 24, 2022
Details:
TACH101, a First-in-Class KDM4 Inhibitor preclinical data demonstrated its potent anti-tumor activity in gastric, esophageal, and colorectal xenograft models and provide support for KDM4 as an important new target for cancer therapy.
Lead Product(s): TACH101
Therapeutic Area: Oncology Product Name: TACH101
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 20, 2022
Details:
TACH101, a pan-inhibitor of KDM4 histone lysine demethylase used in colorectal cancer, especially those harboring microsatellite instability high (MSI-H) signature.
Lead Product(s): TACH101
Therapeutic Area: Oncology Product Name: TACH101
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 08, 2021
Details:
AbCellera is eligible to receive milestone payments and royalties on products that are derived from its antibody discovery platform. In addition, AbCellera has the option to invest in preclinical and clinical development in exchange for an increased share of product sales.
Lead Product(s): TACH204
Therapeutic Area: Oncology Product Name: TACH204
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Recipient: AbCellera
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 03, 2021
Details:
TACH101, Tachyon’s lead product candidate, is a first-in-class, highly-selective inhibitor of KDM4 histone demethylase. AACR is being held virtually from April 10-15 and May 17-21, 2021.
Lead Product(s): TACH101
Therapeutic Area: Oncology Product Name: TACH101
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 10, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
